Article

DDU wins Innovator of the Year Award

The Apicomplexan team won the School of Life Sciences Innovator of the Year Award for the malaria candidate successfully completing completing phase Ib clinical trials.

The results from the first in human (FIH) studies with our malaria candidate, now in clinical development with Merck, have been published, showing a single dose cure at a well-tolerated dose - www.thelancet.com/infection, published online October 26, 2021 https://doi.org/10.1016/S1473-3099(21)00252-8. This huge success in going from fundamental discovery science to a drug in successful clinical trial, highlights the unique on-going capability and impact of the DDU, working with partners, in translating world-class discovery research into new de-risked targets and candidate drugs.

DDU Annual Report

Read about the impact we have made at the Drug Discovery Unit.

Annual Report